This inventor holds 2 USPTO granted patents and 32 published patent applications. Top assignees: Jiangsu Simcere Pharmaceutical Co., Ltd., Simcere Pharmaceutical Co., Ltd., Tuojie Biotech (Shanghai) Co., Ltd.. Active years: 2025-2026.
Company Filing History:
1 out of 2 
1 out of 3 
1 out of 1 Years Active: 2025-2026
Title: Renhong Tang: Innovator in Antibody Development
Introduction
Renhong Tang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on innovative solutions for cancer treatment, showcasing his commitment to advancing medical science.
Latest Patents
Renhong Tang holds a patent for an anti-CD79B antibody, along with its antigen-binding fragment and pharmaceutical applications. This invention relates to a chimeric antibody and a humanized antibody that includes a CDR region of the anti-CD79B antibody. The patent outlines the use of this antibody as an anti-cancer drug, specifically for treating lymphoma, including diffuse large B-cell lymphoma (DLBCL). This groundbreaking work highlights the potential of his invention in improving cancer therapies.
Career Highlights
Renhong Tang is associated with Tuojie Biotech (Shanghai) Co., Ltd., where he continues to innovate in the field of biotechnology. His expertise in antibody development has positioned him as a key figure in the industry. With a focus on creating effective treatments, he has dedicated his career to enhancing patient outcomes through scientific advancements.
Collaborations
Renhong Tang collaborates with notable professionals in his field, including his coworker Cuiqing Yang. These partnerships foster a dynamic environment for research and development, driving forward the mission of creating impactful medical solutions.
Conclusion
Renhong Tang's contributions to antibody development and cancer treatment exemplify the spirit of innovation in biotechnology. His patent for the anti-CD79B antibody represents a significant step forward in therapeutic options for lymphoma patients. Through his work at Tuojie Biotech, he continues to make strides in improving healthcare outcomes.